Efficacy of noninvasive ventilation support on the increase of exercise tolerance in patients with heart failure: a systematic review by Carvalho, Larissa de Andrade et al.
384
S
Y
S
T
E
M
A
T
IC
 R
E
V
IE
W
Correspondence to:: Armèle Dornelas de Andrade – Av.enida Jornalista Anibal Fernandes, s/n – Cidade Universitária – CEP: 50740-560 – Recife (PE), Brazil – E-mail: armeledornelas@yahoo.com
Presentation: Nov. 2013 – Accepted for publication: Oct. 2014 – Conflict of interests: nothing to declare.
Study conducted in the Physical Therapy Department, Universidade Federal de Pernambuco (UFPE) – Recife (PE), Brazil. 
1Graduate Program in Physical Therapy at UFPE – Recife (PE), Brazil. 
2Department of Physical Therapy at UFPE – Recife (PE), Brazil.
DOI: 10.590/1809-2950/13058821042014
ABSTRACT | The aim of this study was evaluate the 
efficacy of noninvasive ventilation (NIV) on improving 
exercise tolerance of patients with heart failure (HF). A 
systematic review was performed in PubMed/MEDLINE, 
LILACS, Cochrane, CINAHL, Scopus and Web of Science 
for randomized and quasi-randomized clinical trials, 
without language and year of publication restrictions. 
Descriptors were defined as ‘heart failure’, ‘noninvasive 
ventilation’, ‘positive-pressure respiration’, ‘interactive ven-
tilatory support’, ‘exercise test’ in addition to the keywords 
‘BIPAP’, ‘CPAP’, ‘IPAP’, ‘EPAP’, ‘NIV’ and their Portuguese 
equivalents. Studies comparing NIV with one or two 
pressure levels to groups without intervention, other 
physiotherapy modalities without positive pressure or a 
sham group were included. Four studies were selected, 
including HF patients of various etiologies, considering 
the staging classification of New York Heart Association. 
Any included work realized the allocation concealment, 
all studies participants underwent blinding, but only two 
trials performed assessors blinding. None of the studies 
have described an intention to treat analysis and did not 
use appropriate statistical methods. All selected trials 
assessed functional capacity and in only two, dyspnea 
was assessed. The intervention protocols of the included 
trials were heterogeneous, three studies underwent a 
single intervention with NIV, two immediately before the 
functional capacity test and another study performed 
NIV during the exercise evaluation. The last trial held 14 
sessions of NIV, with the functional capacity evaluation 
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being performed on days 0, 4, 9 and 14. There is insuffi-
cient evidence on the effectiveness of NIV in increasing 
exercise tolerance.
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RESUMO | O objetivo do estudo foi avaliar a eficácia da 
ventilação não invasiva (VNI) na melhora da tolerância ao 
exercício em indivíduos com insuficiência cardíaca (IC). 
Realizou-se uma busca sistemática nas bases de dados 
PubMed/MEDLINE, LILACS, Cochrane, CINAHL, Scopus 
e Web of science por ensaios clínicos randomizados e 
quasi-randomizados. Os descritores foram: ‘heart failure’, 
‘noninvasive ventilation’, ‘positive-pressure respiration’, 
‘interactive ventilatory support’, ‘exercise test’, além das 
palavras-chave ’BIPAP’, ‘CPAP’, ‘IPAP’, ‘EPAP, ‘NIV’ e seus 
equivalentes em português. Foram incluídos estudos que 
comparassem a VNI com um ou com dois níveis de pres-
são a grupos sem intervenção, a outras modalidades fisio-
terapêuticas sem pressão positiva ou a um grupo sham. 
Foram selecionados quatro estudos, incluindo pacientes 
com IC de diversas etiologias. Os quatro estudos foram 
randomizados e controlados e realizaram o mascaramento 
dos participantes. No entanto, apenas dois trabalhos reali-
zaram o mascaramento dos avaliadores. Em nenhum dos 
artigos selecionados foi feita a análise por intenção de tra-
tar; e apenas um não utilizou métodos estatísticos adequa-
dos. Todos os estudos avaliaram a capacidade funcional 
e dois avaliaram a dispneia. Os protocolos de intervenção 
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INTRODUCCIÓN
Heart failure (HF) is a great worldwide problem that 
affects more than 20 million people¹. In Brazil, this prev-
alence reaches around two million subjects and there 
is an incidence of 240,000 new diagnosed cases every 
year2. This complex syndrome brings several complica-
tions both for the society, like the high socioeconomic 
cost for the health system and early retirement due to 
productivity loss, and for the subject with the disease, 
like physical and psychological problems that cause his/
her social isolation3.
Alterations from the HF are not restricted to the 
cardiac scope. The main symptoms are dyspnea and 
fatigue4, which can limit exercise tolerance. However, 
this population presents a musculoskeletal associated 
involvement due to the low cardiac output5. The pro-
gression of these symptoms creates a decrease in 
the  level of physical activity, which contributes to 
the worsening of the symptoms and exercise intol-
erance. Thus, the functional capacity and quality of 
life of this population is progressively reduced, which 
results in a frequent, high-cost and usually disabling 
clinical condition6. In addition, this cardiac illness is 
associated with frequent hospitalization and re-hos-
pitalization, functional involvement that evolves with 
significant morbidities due to low physical capacity 
and high mortality7,8.
The noninvasive ventilation (NIV) arises as a coad-
juvant therapy in the attempt of improving patients’ 
functional capacity. Use of the NIV has been an option 
to reduce respiratory work, improve blood oxygenation, 
and lung complacency in order to provide an improve-
ment in the tolerance during the physical exercise due 
to its sensible actuation in the cardiorespiratory inter-
action, therefore giving a better cardiac and respiratory 
response during the exercise8-11.
Thus, the present review has as its aim to evaluate 
the NIV effectiveness with continuous pressure or with 
two levels of pressure in the exercise tolerance in adult 
patients from both genders with HF.
METHODOLOGY
It was carried out a systemic review with studies that 
had previously been chosen, and the inclusion criteria 
were: randomized and quasi-randomized controlled 
clinical trials that used the NIV; with continuous pres-
sure or two levels of pressure in the functional capacity 
evaluation, comparing them to a Control Group without 
intervention, to other physiotherapeutic modalities or to 
a sham group, in adult patients from both genders with 
HF. Exclusion criterion considered studies performed in 
worsening periods of the disease. 
foram heterogêneos entre os estudos, ; três artigos realizaram 
uma única intervenção com a VNI. O outro artigo incluído rea-
lizou 14 sessões de VNI, sendo realizada a avaliação da capaci-
dade funcional nos dias 0, 4, 9 e 14. Devido à baixa qualidade 
metodológica dos artigos inclusos, não há evidência suficiente 
sobre a eficácia da VNI no incremento da tolerância ao exercício.
Descritores | Insuficiência Cardíaca; Ventilação Não Invasiva; 
Teste de Esforço.
RESUMEN | El objetivo del estudio fue evaluar la eficacia de la 
ventilación no invasiva (VNI) en la mejora de la tolerancia al ejer-
cicio en sujetos con insuficiencia cardíaca (IC). Se realizó una 
búsqueda sistemática en las bases de datos PubMed/MEDLINE, 
LILACS, Cochrane, CINAHL, Scopus y Web of science por ensa-
yos clínicos aleatorios y casi-aleatorios. Los descriptores fueron: 
‘heart failure’, ‘noninvasive ventilation’, ‘positive-pressure respiration’, 
‘interactive ventilatory support’, ‘exercise test’, además de las pala-
bras clave ‘BIPAP’, ‘CPAP’, ‘IPAP’, ‘EPAP’, ‘NIV’ y sus correspondien-
tes en portugués. Fueron inclusos estudios que comparan la VNI, 
con un o dos niveles de presión, a los grupos sin intervención, 
a otras modalidades fisioterapéuticas sin presión positiva o a 
uno grupo sham. Fueron seleccionados cuatro estudios, incluso 
pacientes con IC de diversas etiologías. Los cuatro estudios fue-
ron aleatorios y controlados y realizaron el enmascaramiento de 
los participantes. Pero solo dos trabajos realizaron el enmascara-
miento de los investigadores. En ninguno de los escogidos, fue 
hecho el análisis por intento de tratamiento y solo uno no utilizó 
métodos estadísticos adecuados. Todos los estudios evaluaron 
la capacidad funcional y dos, la disnea. Los protocolos de inter-
vención fueron heterogéneos entre los estudios; tres artículos 
realizaron solamente una intervención con la VNI. El otro artículo 
incluso hizo 14 sesiones de la VNI, y la evaluación de la capacidad 
funcional fue hecha en los días 0, 4, 9 y 15. En razón de la baja 
cualidad metodológica de los artículos inclusos, no hay eviden-
cia suficiente cuanto a la eficacia de la VNI en el incremento de 
la tolerancia al ejercicio.
Palabras clave | Insuficiencia Cardíaca; Ventilación No Invasiva; 
Prueba de Esfuerzo.
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The primary outcome considered exercise capac-
ity (oxygen consumption; distance) that was assessed 
through the maximum or sub-maximum exercise 
test and dyspnea level — evaluated using subjective 
scales. The oxygen peripheral saturation (SpO2), blood 
pressure (BP), and cardiac frequency (CF) were the 
secondary outcomes.
A systematic search was performed to find articles 
published in indexed journals in the databases PubMed/
MEDLINE, LILACS, Cochrane, CINAHL, Scopus 
and Web of Science. The research strategy was based 
on the standards from the Cochrane Handbook for 
Systematic Reviews of Interventions12. The keywords 
applied for the search followed the description of 
MeSH/DeCS terms, namely: ‘heart failure’, ‘noninvasive 
ventilation’, ‘positive pressure respiration’, ‘interac-
tive ventilator support’, ‘exercise test’. Besides these, 
the following keywords were used: ‘BIPAP’, ‘CPAP’, 
‘IPAP’, ‘EPAP, ‘NIV’. It was also done a research with 
the same words in Portuguese. The words were com-
bined using the Boolean operators ‘OR’, ‘AND’ and 
‘NOT AND’. There were no linguistic and publica-
tion year restraints. The investigation was carried out 
between April and May 2013.
In the initial phase, two independent reviewers (LAC 
and CRL) identified and evaluated titles and abstracts on 
the computer screen, in order to choose those that would 
meet eligibility criteria. Potentially relevant studies that 
raised doubts were retained for a posterior analysis of the 
complete text. In cases of disagreement in the process 
of selection and analysis of the articles, a third evaluator 
(DCB) would take part in the evaluation.
Data collection from the chosen studies was per-
formed by two independent evaluators. Extracted data 
were: eligibility criteria, study population, participants’ 
flow, intervention details, outcome measures, results, 
and bias risk.
Two independent evaluators analyzed studies that 
met the inclusion criteria as to the methodological 
quality using PEDro scale, based on the Delphi list. 
PEDro scale was developed to be used in clinical tri-
als and, recently, it is one of the most used in Physical 
Therapy13,14. It allows a total score of ten points. For each 
criterion presented in it, a score of one or zero point 
may be attributed.
In the end of data collection, it was seen the possi-
bility of preparing a meta-analysis. However, this was 
not possible due to heterogeneity of the included stud-
ies and lack of data.
RESULTS
The search strategy was ample and resulted in 1,359 
titles. From these, 1,300 were excluded by titles for not 
presenting the inclusion criteria. Of the 59 remaining 
studies, 12 were discarded due to duplicity, 19 were 
deviated due to not complying with the theme or 
inappropriate study design. Twenty-eight studies were 
chosen, which were assessed through abstract analysis, 
and 18 were excluded for not presenting inclusion cri-
teria. The ten retained articles had their texts completely 
read, of which six did not present eligibility criteria, as 
described in Figure 1.
Therefore, four studies were included for quali-
tative synthesis8-11. Studies included 58 adults with 
HF diagnosis, 18 women and 40 men, whose average 
of age varied from 33 to 68 years old. These stud-
ies were originally from Brazil8,9,11 and Canada10 and 
the population was composed by subjects with HF 
of several etiologies. However, two of the analyzed 
studies10,11 included only the disease congestive form. 
Staging was different between the studies, three of 
them8,9,11  included patients of II and III functional 
class and only one investigation10 had subjects of II-IV 
functional class. Nevertheless, they were always using 
the classification recommended by the New York Heart 
Association (Table 1).
Three studies8,9,11 evaluated the NIV effect with con-
tinuous pressure in the exercise tolerance through the 
6-minute walking test, which is an effort sub-maximum 
exercise test. Only one of the studies10 evaluated and 
compared the NIV effect with two levels of pressure 
and with continuous pressure in the exercise tolerance, 
using the sub-maximum test of constant load in cyclo-
ergometer to assess functional capacity. There was also 
a variation as to the Control Group: in two studies8,9, 
subjects did not perform any kind of NIV. However, in 
two others10,11, they did the NIV in placebo with low 
pressure levels. 
As to the control of patients’ selection, all studies 
mentioned performing randomization8-11. However, only 
one of the included papers9 specified the used method: a 
raffle in an opaque and sealed envelope. As to the allo-
cation secrecy, a study9 reported that the envelope used 
to keep secrecy was the opaque one. Nonetheless, none 
of the analyzed studies8-11 specified if one independent 
person performed the randomization.
In one article11, there was an outcome selective descrip-
tion, besides expression of its results only in gain percentage 
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Figure 1. Research and selection of studies for the systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Studies identified through electronic search in databases: PubMed/MEDLINE (n=421), LILACS (n=54),  
Cochrane (n=113), CINAHL (n=25), Scopus (n=591) and Web of Science (n=155). 
Chosen studies (n=59)
1,300 were excluded from their title
Chosen studies (n=28)
Complete articles evaluated for eligibility (n=10)
Studies included in the qualitative synthesis (n=4)
• Duplicity=12
• Not the correct theme=18 
• Inappropriate study designs=1
Studies excluded from reading the abstract (n=18)
Chermont et al.8
Lima et al.9
O’Donnell et al.10
Wittmer et al.11 
Did not meet inclusion criteria (n=6)
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Table 1. Characteristics of the included studies
Author, 
Country
Population
Age 
(mean)
Diagnosis
Criteria used for 
staging
Intervention protocol (Type of therapy)
Chermont 
et al.8
Brazil
G: 4 women 
and 8 men
G: 56±12
HF (ischemic 6 
and idiopathic 
6)
LVEF<45%
NYHA
II/III: 4/8
Type of therapy: NIV – CPAP 4 to 6 cmH
2
O (individual pressure) through 
nasal blinding in decubitus position at 45°, before the 6’WT. Placebo – 
ventilator support performance of 0-1 cmH
2
O in decubitus position at 
45°, before the 6’WT. 
Frequency: once in each experimental situation, in different days (does 
not report the interval period).
Duration: NIV and Placebo – 30 minutes.
Functional capacity test: 6’WT.
Instrument: CPAP (Traquility, Healthdyne Technologies, Marietta, GA).
Lima et al.9
Brazil
NIV: 
2 women 
and 4 men;
Control: 
1 woman and 
5 men; 
NIV:
47.5±9.1
Control: 
45.1±12.1 
HF 
(Hypertensive 
5, ischemic 5, 
others 2)
LVEF<45%
NYHA
II/III: 2/10
Type of therapy: NIV – CPAP performance (10 cmH
2
O) before the 6’WT 
Control – without performance of ventilator support.
Frequency: once.
Duration: NIV – 30 minutes.
Functional capacity test: 6’WT.
Instrument: CPAP (without specification).
O´Donnell 
et al.10
Canadá
G: 1 woman 
and 11 men.
G: 61±4 CHF (ischemic
and idiopathic)
NYHA II-IV
Type of therapy: NIV – CPAP (4.8±0.2 cmH
2
O) during the constant load 
test in cycloergometer
NIV 2 – SP (4.8±0.2 cmH
2
O) during the constant load test in cycloergometer
Placebo (CPAP 1 cmH
2
O) during the constant load test in 
cycloergometer (75% of the maximum work). 
Frequency: once in every experimental situation with an interval of 1 
hour between them.
Duration: CPAP/SP/ Placebo during the Exercise test in cycloergometer.
Functional capacity test: the constant load test in in cycloergometer.
Instrument: Respironics Ventilator (Respironics, Murrysville, PA)
Wittmer 
et al.11
Brazil
NIV:
6 women 
and 6 men; 
Control:
4 women 
and  6 men.
NIV:
59.8±3.7 
Control: 
52.7±11.4
CHF (idiopathic 
13, alcoholic 1, 
after rheumatic 
fever 8)
NYHA II and III
Type of therapy: NIV – CPAP performance (8 cmH
2
O), 100 meters walk 
every day, respiratory exercises
Control – 100 meters walk every day, respiratory exercises.
Frequency: NIV and Control – 14 sessions.
Duration: NIV – 30 minutes of CPAP.
Functional capacity test: 6’WT.
Instrument: CPAP (without specifications).
HF: heart failure; LVEF: left ventricle ejection fraction; NYHA: New York Heart Association; 6’WT: 6-minute walking test; NIV: noninvasive ventilation; CPAP: continuous positive pressure; G: group; CHF: 
congestive heart failure; SP: support pressure
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(value after treatment – value before treatment/value before 
treatment x 100). It also analyzed its results, comparing 
the same group before and after intervention. Only one 
article11 mentioned sampling loss and none performed 
analysis with treatment intention. All articles8-11 performed 
participants’ blinding. However, only two did evaluator’s 
blinding8-11. Study scoring, according to PEDro scale, is 
presented in Table 2.
With regard to outcome evaluation, with the exception 
of one paper11, in which results were not clearly exposed, 
the functional capacity was assessed in a reproducible 
manner in three studies8-10. As to the dyspnea outcome, 
only two studies tried to analyze data9,10, and both used 
Dyspnea Borg’s Scale. In one of the articles8, there was 
data collection through Dyspnea Borg’s Scale every two 
minutes during the 6’WT, but this was not presented. 
As to the secondary outcomes, two studies9,10 evaluated 
the oxygen saturation outcomes and three8,10 assessed BP 
and CF (Table 2).
After observing intervention protocols in every study, 
a great heterogeneity was seen. In three studies8-10, only 
one NIV session was performed, and two studies8,9 did 
it right after the functional capacity test (FCT), and the 
remaining study19 did the NIV during the FCT. The 
other included article11 performed 14 NIV sessions, and 
the capacity functional evaluation happened in days 0, 
4, 9, and 14.
Studies had different information not only with 
regard to the number of sessions, but also to the 
used pressure. While two studies9,11 established the 
continuous pressure (CPAP) in 10 and 8 cmH2O, 
respectively, other two ones8,10 performed one pressure 
titling. A study8 was titled based on subject’s satisfac-
tion from a previous evaluation, adopting a CPAP of 
3 to 6 cmH2O. In addition, the other included study10 
titled the pressure based on the benefits also found 
from a previous evaluation, adopting the same value 
as in the continuous pressure phase and for the two-
pressure levels phase, mean of the adopted pressures 
was of 4.8 cmH2O. In three articles8,10,11, intervention 
groups were described with details including impor-
tant information, such as the positioning during NIV 
administration and used interface. Intervention groups 
and their respective protocols, outcomes and methods 
applied by the authors for measurement and interven-
tion results are exposed in Table 1. Two studies were 
designed with the crossover kind, one8 did not men-
tion the washout period between the experimental and 
placebo phases. Another research8 opted in perform-
ing the three effort sub-maximum exercise tests – two 
experimentals and one placebo – at the same day, with 
a resting period of one hour between them.
Sampling calculation was performed in only one 
study8, which used literature information to carry it out. 
None of the articles defined the clinically important dif-
ference in the functional capacity or dyspnea evaluation. 
Furthermore, none of the analyzed articles presented 
conflicts of interest.
Table 2. Evaluation of outcomes
NIV: noninvasive ventilation; 6’WT: 6-minute walking test; SP: support pressure; CPAP: continuous positive pressure; Pre NIV: basal value of the noninvasive ventilation group; Post NIV: post-test value of the 
noninvasive ventilation group. Pre Control: basal value of the control group; Post Control: post-test value of the control group; VO
2
: oxygen consumption.
Author, Country Type of outcome evaluations Functional capacity (instrument) Dyspnea (instrument)
Chermont et al.8
Brazil
After the intervention and placebo phases 
(intergroup analysis).
Distance (6’WT)
NIV: 507±33 meters
Placebo: 446±36 meters
p≤0.001
Not assessed
Lima et al.9
Brazil
Before and after for the intervention 
group and for the control group (intra and 
intergroup analysis).
Distance (6’WT)
NIV: 534±89.91 meters
Control: 420.6±73.8 meters
p≤0.03
Borg
NIV: 11±0.8
Control: 13.1±1.16
p≤0.009
O´Donnell et al.10
Canada
After the intervention and placebo phases 
(intergroup analysis).
VO
2
 (Constant load test in cycloergometer; 
Ergometrics 800S; SensorMedics)
SP: 1.47±0.14 min N/S
CPAP: 1,46±0,14 L/min NS 
Control: 1.5±0.14 L/min
Borg
SP: 5.5±0.5 NS
CPAP: 5.1±0.5 NS
Control: 5.2±0.5 
Wittmer et al.11
Brazil
At days 0, 4, 9, and 14 for the intervention 
and control groups (intragroup analysis).
Distance (6’WT)
Pre NIV: 344±25 meters
Post NIV: increase of 28% p≤0.05
Pre control: 341±16 meters
Post control: not reported p≤NS
Not assessed
389
Carvalho et al. Noninvasive ventilation on functional capacity
DISCUSSION
Due to the methodological heterogeneity of clinical 
trials8-11 with regard to the applied protocols, as well as 
to the clear lack of demonstration of results, the effec-
tiveness of NIV was not evident in the increment of 
exercise tolerance in subjects with HF. In addition, all 
studies analyzed their outcomes based only on the sta-
tistical significance, and it was not possible to calculate 
the magnitude of the treatment effect. The method-
ological aspects of the included articles deserve some 
considerations.
Some methodological artifices are used in order to 
reduce bias risk. The best way to minimize the selec-
tion bias with certification of the treatment effect is 
the proper performance of a randomization process 
and allocation secrecy. It was observed that a treat-
ment can be overestimated in up to 40% when such 
items are not properly carried out15,16. Besides, the ran-
dom allocation of the participants of a study is done 
to balance the characteristics of the groups, avoid-
ing confusion factors16. With regard to the selection 
control of participants, it was seen that all included 
studies8-11 mentioned performing the randomization 
process. However, only one of the articles9 described 
the adopted process, despite the fact that it is not an 
appropriate method. On the other hand, as to the 
allocation secrecy, a study9 reported that the envelope 
used to keep secrecy was opaque; however, none of the 
analyzed studies specified if an independent subject 
performed the allocation. By knowing the importance 
of these methodological aspects, once they avoid over-
estimation of the treatment effect, it is possible that 
different results may be evidenced in studies that per-
form randomization and allocation secrecy correctly, 
suggesting a lower effectiveness of the technique.
In addition, to try minimizing the selection bias of 
the studies, very well established inclusion criteria were 
determined in order to homogenize the studied sample. 
Nevertheless, one of the studies11 evidenced a difference 
in the basal values of the ejection fraction (EF) for the 
studied groups. Therefore, the highest EF was for the 
intervention group compared to the Control Group. EF 
is an important variable able to interfere in the blood 
supply and consequently in the functional capacity of 
the assessed subjects17.
Participants’ blinding, although not possible of 
being performed in all situations, is as necessary 
NIV: noninvasive ventilation; SP: support pressure; CPAP: continuous positive pressure.
Table 2. Evaluation of outcomes (continuation)
Author, Country Type of outcome evaluations Heart frequency (instrument)
Systolic blood pressure
Diastolic blood pressure 
(instrument)
Oxygen Peripheral Saturation 
(instrument)
Chermont et al.8 
Brazil
After the intervention and 
placebo phases (intergroup 
analysis).
NIV: 99±4 bpm
Placebo: 91±4 bpm
p≤0.03
Non-specified instrument
NIV: 129±6 mmHg
Placebo: 136±8 mmHg
p≤0.220
NIV: 60±5 mmHg
Placebo: 58±5 mmHg
p≤0.312
Non-specified instrument
Not assessed
Lima et al.9
Brazil
Before and after for the 
intervention group and for 
the control group (intra and 
intergroup analysis).
NIV: 99.6±13 bpm 
Control: 117.8±19.3 bpm
p≤0.086
Non-specified instrument
NIV: 140±12.6 mmHg
Control: 150±8.9 mmHg
p≤0.145
NIV: 101.6±13.2 mmHg
Control: 105±5.4 mmHg
p≤0.583
Non-specified instrument
NIV: 96.1±1.8%
Control: 93.6±1.5%
p≤0.02
Non-specified instrument
O´Donnell et al.10
Canada
After the intervention and 
placebo phases (intergroup 
analysis).
SP:119±7 bpm NS
CPAP: 122±8 bpm NS
Control: 121±7 bpm
Electrocardiographic Monitor 
(Cardiovit CS-6/12Z; Schiller, 
Baar, Switzerland).
Not assessed
SP: 97.6±0,3% NS
CPAP: 97.5±0.2% NS
Control: 97.6±0.3%
Pulse oximeter (503 pulse 
oximeter; Criticare Systems, 
Wakesha, WI)
Wittmwe et al.11
Brazil
At days 0, 4, 9, and 14 for 
the intervention and control 
groups (intragroup analysis).
Not assessed Not assessed Not assessed
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as the randomization or allocation secrecy, since it 
decreases the probability that expectations of the 
investigators interfere in the real benefit of the treat-
ment18. All included studies in this review performed 
participants’ blinding8-11. Blinding of examiners and 
evaluators of the outcomes, which may be performed 
in all analyzed studies, was only done in two papers8,11. 
This item is necessary since it prevents execution and 
mensuration bias.
Only one clinical trial8 performed sampling calculation, 
which was based on literature data. Sample calculation 
is important for inferences and extrapolations of the 
results found for the general population. Only one of the 
included articles9 was classified as pilot study in the title. 
Therefore, more controlled and randomized clinical tri-
als are needed with performance of sampling calculation 
to ensure a sufficient power, as well as a higher external 
validity of the results that were found.
Another important item to minimize the overestima-
tion of results is the analysis with treatment intention, 
which compares patients in the group where they were 
primarily allocated, regardless of the sample loss19. Use 
of this analysis is only possible when there are com-
plete data with regard to all randomized subjects. Only 
one study11 reports patient loss. However, the patient’s 
inclusion and exclusion flowchart was not exposed in 
any analyzed paper. Absence of clarity in the exposure 
of subjects’ inclusion and exclusion and in the results 
concerning each outcome leads to a bias risk. Absence 
of data is a relevant bias in the effect estimation20, which 
established the outcome selective description. This hap-
pens because studies with positive results are more easily 
published. Therefore, it is needed clarity and objectivity 
in the demonstration of results on outcomes, on the con-
duction of the volunteer during the research, as well as 
proper data treatment, which must be performed between 
groups after the intervention, but not before and after 
in the same group. 
After qualitatively assessing the results presented, we 
observed a fragility in the internal validity of the stud-
ies, since many applied strategies, which could be used 
to minimize bias risk, did not do it correctly. Decision-
making is based on the current concept of practice based 
on evidence, which requires choice of better evidence 
levels together with the clinical experience of the pro-
fessional and patient’s choice20. Thus, studies with more 
methodological scope need to be performed in order to 
better fundament the use of NIV as a coadjuvant therapy 
with physical exercises in HF subjects.
CONCLUSION
The present systematic review was inconclusive as to 
the efficacy of NIV in the increment of exercise toler-
ance in subjects with HF. From the assessed studies, 
it was concluded that there is a low methodological 
quality due to the high bias risk in the available stud-
ies about the present theme, thus it was not possible to 
recommend NIV in this context. Therefore, we recom-
mend the performance of randomized and controlled 
trials following a stricter methodological criterion, with 
appropriate sampling power, which controls allocation 
secrecy and evaluator’s blinding. It is also needed more 
clarity as to data exposition in order to make feasible 
the analysis of the size effect of treatment for critical 
and important outcomes.
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